Premier Biotech (“Premier” or the “Company”), a fully integrated provider of drug and alcohol solutions, announced today that Rod Weis has joined the Company as its new Chief Revenue Officer (CRO). This strategic hire reinforces Premier’s commitment to innovation and growth in the drug and alcohol testing industry.

Rod brings decades of experience driving revenue growth and building high-performing teams in enterprise solutions and compliance services. Most recently, he served as Vice President, Enterprise Sales at UKG, a prominent Workforce Operating Platform. Before that, he was CRO, Americas at First Advantage, a leading global provider of employment background screening, identity, and verification solutions.

“Rod is a proven leader and his experience at First Advantage and UKG gives him a deep understanding of organizations’ hiring and workforce management needs, including the importance of finding the right drug testing solution,” said Matt Michalik, CEO of Premier Biotech. “We see a tremendous opportunity to expand our market leadership with our OralTox® and OT-Scan® solutions as demand for an integrated oral fluid solution accelerates. Rod’s experience and direction will help us capitalize on that momentum and cement Premier as the clear market leader.”

Rod joins Premier at a time of extraordinary momentum and market opportunity. The Company has aggressively expanded its capabilities, strengthened its brand, and introduced cutting-edge technologies that are reshaping the drug and alcohol testing industry. With proprietary oral fluid solutions like OralTox® and OT-Scan® leading the way and a full-service portfolio that includes urine testing, lab confirmations, and integrated technology platforms, Premier is uniquely positioned to capture significant growth. As CRO, Rod will lead the charge in executing the Company’s go-to-market strategy designed to accelerate adoption, deepen customer relationships, and affirm Premier’s position as the undisputed leader in this space.

“Premier Biotech is defining the future of drug and alcohol testing and has been at the leading edge of rapid oral fluid testing for years, but this is a particularly exciting time to join,” said Rod Weis. “This is an incredible opportunity, and I’m excited to help drive bold growth strategies that keep Premier at the forefront of innovation and leadership. Legislative, social, and workforce evolution continue to change the landscape of drug testing, and Premier Biotech is extremely well positioned to take advantage of the circumstances and continue to drive change through innovation.”

About Premier Biotech

Premier Biotech delivers rapid and innovative diagnostic solutions that promote health, safety and compliance. The Company is a leading provider of proprietary oral fluid (OralTox® and OT-Scan®) and other products, services and technology solutions designed to simplify and provide a seamless end-to-end experience for customers. Premier differentiates itself through its fully integrated service offering that is augmented with high levels of service, technical expertise and configurability. The Company’s integrated offering is utilized in workplace, government, and healthcare settings. For more information, visit premierbiotech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251202274664/en/

As CRO, Rod will lead the charge in executing the Company’s go-to-market strategy designed to accelerate adoption, deepen customer relationships, and affirm Premier’s position as the undisputed leader in this space.